nearly all postmenopausal women with early-stage,hr positive breast cancer are treated with aromatase inhibitors. but these drugs cansignificantly compromise bone health and up the risk of fractures. i'm gabe garza withyour latest health news. for this reason, high-risk patients are often prescribed theosteoporosis drug denosumab to reduce their risk of fractures. but denosumab may haveanother benefit, a new study found. adding denosumab to aromatase inhibitor therapy mayimprove disease-free survival in postmenopausal women with early-stage, hr positive breastcancer. for this study, researchers looked at over 3,000 postmenopausal women with early-stage,hr positive breast cancer. they were then split into two groups. one group was given60 milligrams of denosumab once every six
months, while the other was given a placebo.after an average of four years, the patients on denosumab had an 18 percent reduced riskof cancer recurrence compared with the patients on placebo. talk to your doctor about allyour treatment options if you have cancer.